★ Founding Contributor
DENNIS OLYMPIOS
LINKEDSUPERPOWERS · CEO profile ↗
For the last 12 years, Dennis Olympios has been globally known for his work in online Thought Leadership, personal branding, and strategic visibility. He has helped elevate the personal brands of thousands of CEOs, Entrepreneurs & C-level executives from some of the world’s largest Fortune 500 companies, including Microsoft, Google, IBM, Nike, and Pfizer, and has built a following of over 6 million people across social media.
6 stories
Bylines
Features· Sep 28, 2026
Gerard Wouters on Unlearning the Pressure to Prove Yourself
The founder of the Foundation Taoist Health Institute, draws on his management experience and seven years of Taoist training to challenge how leaders think about performance, appreciation and personal boundaries.
Features· Sep 9, 2026
Arthur Rego: Losing Everything Taught Him What “Never Give Up” Really Means
"Leadership is not measured simply by the authority we possess, but by the results we help create, the people we help develop and the positive difference we leave behind."
Features· Sep 1, 2026
Patrick R. Coyle: Following the Patient to Understand the Economics
The experienced life sciences finance executive offers valuable insights into how patient access and commercial performance can be understood as parts of the same system.
Features· Aug 25, 2026
The Most Overlooked Moment in Healthcare. How Shawn Gibbs Is Reimagining the Patient Gown.
The co-founder and CEO of GIV Gowns believes dignity, coverage and clinical access should no longer be treated as competing priorities.
Features· Aug 18, 2026
Ton van de Ven Wants to Make Business Networking Accountable
At INC. Business Matchmakers, access is curated, introductions are purposeful, and the real scorecard begins after the meeting.
Features· Aug 15, 2026
Silencing the Virus Within: William Brandler’s Bid to Turn “Jumping Genes” Into Precision Medicines
Inspired by Nobel laureate Barbara McClintock, the scientist-engineer behind L1 Therapeutics is combining genomics, open-source software and AI-assisted development to pursue one of medicine’s harder questions: when does dormant, virus-like DNA become treatable disease biology?